The impact of 99mTc-DTPA orbital SPECT in patient selection for external radiation therapy in Graves' ophthalmopathy

Nuclear Medicine Communications

Volumn 34, Issue 2, 2013, Pages 108-112

  Szabados, Lajos ^a   Nagy, Endre V ^a   Ujhelyi, Bernadett ^a   Urbancsek, Hilda ^a   Varga, József ^a   Nagy, Edit ^a   Galuska, László ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

99mTc DTPA; Graves' ophthalmopathy; orbital radiation therapy; orbital SPECT

Indexed keywords

PENTETATE TECHNETIUM TC 99M; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CAMERA; CLINICAL ARTICLE; ENDOCRINE OPHTHALMOPATHY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; MALE; PATIENT SELECTION; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; MIDDLE AGED; ORBIT; RADIATION EXPOSURE; SCINTISCANNING; TIME;

ADULT; AGED; FEMALE; GRAVES OPHTHALMOPATHY; HUMANS; MALE; MIDDLE AGED; ORBIT; PATIENT SELECTION; RETROSPECTIVE STUDIES; TECHNETIUM TC 99M PENTETATE; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 84871616524     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32835c19f0     Document Type: Article

References (21)

1. Bartley GB, Gorman CA. Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol 1995; 119:792-795.
2. Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993; 329:1468-1475.
3. Ravin JG, Sisson JC, Knapp WT. Orbital radiation for the ocular changes of Graves' disease. Am J Ophthalmol 1975; 79:285-288.
4. Wiersinga WM, Prummel MF. Therapeutic controversies. Retrobulbar radiation in Graves' ophthalmopathy. J Clin Endocrinol Metab 1995; 80:345-347.
5. Galuska L, Leovey A, Szucs-Farkas Zs, Garai I, Szabo J, Varga J, et al. SPECT using 99mTc-DTPA for the assessment of disease activity in Graves' ophthalmopathy: a comparison with the results from MRI. Nucl Med Commun 2002; 23:1211-1216.
6. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997; 47:9-14.
7. Dominguez ML, Llana B, Zeidan N, Suarez JP, Alvarez A, Raigoso P, et al. In 111-Octreotide scintigraphy in orbital Graves' disease: a parameter to predicts the clinical response to somatostatin analogs therapy? Eur J Nucl Med Suppl 2002; 29 (Suppl 1):P-594.
8. Prummel MF, Wiersinga WM. Medical management of Graves' ophthalmopathy. Thyroid 1995; 5:231-234.
9. Galuska L, Varga J, Szucs-Farkas Z, Garai I, Boda J, Szabo J, et al. Active retrobulbar inflammation in Graves' ophthalmopathy visualized by Tc-99m DTPA SPECT. Clin Nucl Med 2003; 28:515-516.
10. Mayer EJ, Fox DL, Herdman G, Hsuan J, Kabala J, Goddard P, et al. Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur J Radiol 2005; 56:20-24.
11. Prummel MF, Gerding MN, Zonneveld FW, Wiersinga WM. The usefulness of quantitative orbital magnetic resonance imaging in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2001; 54:205-209.
12. Ott M, Breiter N, Albrecht CF, Pradier O, Hess CF, Schmidberger H. Can contrast enhanced MRI predict the response of Graves' ophthalmopathy to orbital radiotherapy? Br J Radiol 2002; 75:514-517.
13. Szucs-Farkas Z, Toth J, Balazs E, Galuska L, Burman KD, Karanyi Z, et al. Using morphologic parameters of extraocular muscles for diagnosis and follow-up of Graves' ophthalmopathy: diameters, areas, or volumes? Am J Roentgenol 2002; 179:1005-1010.
14. Krassas GE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 1995; 42:571-580.
15. Burggasser G, Hurtl I, Hauff W, Lukas J, Greifeneder M, Heydari B, et al. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves' disease. J Nucl Med 2003; 44:1547-1555.
16. Hauser W, Atkins HL, Nelson KG, Richards P. Technetium-99m DTPA: a new radiopharmaceutical for brain and kidney scanning. Radiology 1970; 94:679-684.
17. Alevizaki-Harhalaki M, Alevizaki C, Georgiou E, Proukauis C, Ikkos D. Increased Tc-99m DTPA uptake in active Graves' ophthalmopathy and pretibial myxoedema. J Nucl Med 1983; 24:174-176.
18. Galuska L, Leovey A, Szucs-Farkas Z, Szabados L, Garai I, Berta A, et al. Imaging of disease activity in Graves' orbitopathy with different methods: comparison of 99mTc-DTPA and 99mTc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores. Nucl Med Commun 2005; 26:407-414.
19. Galuska L, Varga J, Szucs-Farkas Z, Nagy EV, Burman KD. Differences in SPET analysis of thyroid-associated orbitopathy. Eur J Nucl Med Mol Imaging 2004; 31:793-795.
20. Ujhelyi B, Erdei A, Galuska L, Varga J, Szabados L, Balazs E, et al. Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy. Thyroid 2009; 19:375-380.
21. Bland JM, Altman DG. Statistical methods of assessing agreement between methods of clinical measurements. Lancet 1986; 8476:307-310.